Titre:
  • The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
Auteur:Remon, Jordi; Menis, Jessica; Hasan, Baktiar; Peric, Aleksandra; De Maio, Eleonora; Novello, Silvia; Reck, Martin; Berghmans, Thierry; Wasag, Bartosz; Besse, Benjamin; Dziadziuszko, Rafal
Informations sur la publication:Clinical lung cancer
Statut de publication:Publié, 2017-03
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:AZD9291
Blood
EGFR mutation
Gefitinib
Lung
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1525-7304
info:doi/10.1016/j.cllc.2017.02.005
info:pii/S1525-7304(17)30048-7
info:scp/85015727416
info:pmid/28341106